ArticleCase reports in dentistry2025
COVID-19-Associated Mucormycosis Mimicking Odontogenic Pain: A Report of Three Cases.
Article in Case reports in dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to present three cases of COVID-19-related mucormycosis mimicking endodontic pain and to discuss the relevant dental and medical literature for this potential life-threatening disease. Summary: Mucormycosis (previously called zygomycosis) is a rare but serious infection caused by a group of fungi called mucormycetes. Mucormycosis mainly affects people who are medically compromised and have systemic health conditions or take drugs that lower their immune response. There has been an increase in case reports/series of mucormycosis in individuals diagnosed with COVID-19. This is likely attributable to the high doses and prolonged use of corticosteroids in the treatment of hospitalized COVID-19 patients. This increase in the prevalence of the condition is of importance, primarily because the fatality rate of patients with mucormycosis is high. Moreover, rapid growth and dissemination into soft tissue and bone with angioinvasion of the fungus are common, and delays in diagnosis can be fatal. This report describes three cases of mucormycosis that were associated with COVID-19 and presented with symptoms that mimicked odontogenic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.